BioRestorative Therapies, Inc.
BRTX
$0.18
-$0.01-6.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -54.73% | -94.95% | 240.40% | -28.57% | 124.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -54.73% | -94.95% | 240.40% | -28.57% | 124.35% |
| Cost of Revenue | -51.52% | -41.76% | 33.85% | -- | -- |
| Gross Profit | -55.00% | -99.44% | 256.66% | -36.86% | 107.25% |
| SG&A Expenses | 18.30% | 6.34% | 25.21% | 0.95% | -52.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.66% | 47.62% | 41.08% | 16.61% | -15.64% |
| Operating Income | -42.20% | -62.18% | -33.88% | -16.99% | 16.47% |
| Income Before Tax | -96.05% | -178.39% | 34.06% | -140.17% | 28.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.05% | -178.39% | 34.06% | -140.17% | 28.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.05% | -178.39% | 34.06% | -140.17% | 28.99% |
| EBIT | -42.20% | -62.18% | -33.88% | -16.99% | 16.47% |
| EBITDA | -42.91% | -63.33% | -34.34% | -16.95% | 16.94% |
| EPS Basic | -63.41% | -147.99% | 38.73% | -91.72% | 59.02% |
| Normalized Basic EPS | -3,646.55% | -147.98% | 38.74% | -91.69% | 101.89% |
| EPS Diluted | -63.41% | -147.99% | 38.73% | -91.72% | 59.02% |
| Normalized Diluted EPS | -3,646.55% | -147.98% | 38.74% | -91.69% | 101.89% |
| Average Basic Shares Outstanding | 19.95% | 12.25% | 7.62% | 25.27% | 73.34% |
| Average Diluted Shares Outstanding | 19.95% | 12.25% | 7.62% | 25.27% | 73.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |